PCRX vs XZO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PCRX · Pacira BioSciences$36.43 ▲ 0.03%
XZO · Exzeo Group$16.29 ▼ 5.46%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PCRX +57.9%
- XZO -15.9%
Head to head
| Metric | PCRX | XZO |
|---|---|---|
| Price | $36.43 | $16.29 |
| Change today | ▲ 0.03% | ▼ 5.46% |
| Market cap | $1.46B | $1.46B |
| Return, 3 months | +49.1% | +2.6% |
| Return, year to date | +40.8% | -32.8% |
| Return, 1 year | +65.2% | -15.9% |
| P/E (TTM) | 39.2 | 17.1 |
| P/B | 2.1 | 4.9 |
| P/E percentile vs own 5y | 79th | 66th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +6.2% | +3.0% |
| Net profit growth (YoY) | +196.0% | +7.4% |
| Gross margin | 79.2% | 62.3% |
| Operating margin | 2.5% | 48.5% |
| Net margin | 2.0% | 39.1% |
| Return on equity | 2.0% | 50.4% |
| Analyst target vs. price | -4.5% | – |
| Analyst buy share | 0% | 100% |
| RSI (14) | 83 | 46 |
| 30-day volatility | 107.0% | 60.1% |
| Max drawdown, 1 year | -28.2% | -48.2% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Hold | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PCRX is the largest of the group by market value.
- PCRX has returned the most over the past year.
- XZO carries the lowest trailing P/E.
- PCRX is growing revenue fastest.
- XZO keeps the most profit per dollar of sales.
- XZO has been the calmest stock over the last 30 days.